Tempsens Instruments IPO: 105% GMP, Subscription & Allotment

The Tempsens Instruments IPO has quickly become one of the most closely watched public issues, with a 105% grey market premium (GMP) and exceptionally strong investor demand.

The ₹650-crore IPO reportedly received subscription of more than 38 times by Day 3, while the final subscription crossed 177 times. INDmoney reported an overall subscription of around 184.07 times.

These numbers highlight strong investor interest. But they also raise an important question: Are investors attracted by Tempsens's business fundamentals, or are they primarily chasing potential listing gains?

105% GMP Puts the IPO in the Spotlight

With the IPO price band capped at ₹300 per share, a GMP of around 105% suggested an unofficial expected listing price of nearly ₹600.

On paper, that represents a significant potential gain for IPO investors. However, GMP is based on unofficial market activity and does not guarantee the actual listing price.

The sharp GMP has also increased the possibility of FOMO among investors. When an IPO appears capable of delivering substantial listing gains, demand can be driven not only by fundamentals but also by the fear of missing out.

The OFS Factor: Where Is the IPO Money Going?

One factor investors should look beyond is the IPO's structure.

Of the ₹650-crore issue, approximately ₹95 crore comes from a fresh issue, while around ₹555 crore is an Offer for Sale (OFS).

In simple terms, a large portion of the issue proceeds will go to existing shareholders selling their shares rather than directly to the company.

An OFS is not automatically a red flag. However, investors should understand this distinction before judging the IPO solely on subscription numbers or GMP.

Tempsens Has a Business Story Behind the Hype

The IPO's popularity isn't based entirely on speculation. Tempsens has reported growth in both revenue and profit.

According to the reported figures, revenue increased from ₹382.47 crore in FY2025 to ₹455.86 crore in FY2026, while profit rose from ₹62.56 crore to ₹71.07 crore.

This suggests that the company has demonstrated business growth alongside the strong market interest surrounding its IPO.

However, strong business performance does not automatically mean the stock will deliver strong returns after listing. At a high GMP and massive subscription levels, investor expectations are already elevated.

What Investors Should Watch After Listing

The biggest test for Tempsens will begin once the stock enters the listed market.

If the company lists close to the levels indicated by the GMP, early investors could see significant gains. But if the actual listing price falls well below market expectations, the same enthusiasm that drove demand could potentially turn into selling pressure.

For investors, the key factors to watch will be post-listing valuation, earnings growth, profitability, and how the market values the company beyond the initial IPO excitement.

The Bottom Line

Tempsens Instruments has certainly won the IPO popularity contest, but popularity alone doesn't determine long-term performance.

The company's growth in revenue and profit provides a fundamental story, while the 105% GMP and exceptionally high subscription show just how strong investor expectations have become.

The real question now isn't simply whether Tempsens can deliver a strong listing.

The bigger question is whether the company's fundamentals can justify the expectations created before the stock even begins trading.

Disclaimer: This article is for informational purposes only and should not be considered investment advice. GMP is unofficial and can change rapidly. Investors should conduct their own research before making any investment decision.